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A B S T R A C T
Introduction: Optimal cancer treatment with targeted agents requires rapid, comprehensive and accu-
rate molecular assays to analyse actionable oncogenic mutations across multiple tumour types.
Materials and Methods: We describe a PCR panel based on the 384 well TaqMan Array® (Thermo Fisher
Scientiﬁc). This allows measurement of common RAS (NRAS and KRAS), EGFR and BRAF mutations in a
single assay (the REB Array), analysing 44 mutations in 7 samples per plate. This retrospective study in-
cludes 96 patients with NSCLC (n = 42), colorectal cancer (n = 26), and melanoma (n = 28) with previous
mutational analysis. Samples with discrepant results were sequenced to conﬁrm the result.
Results: The REB achieved 93% concordance with the Therascreen EGFR assay (Qiagen), 95% concor-
dance with the KRAS castPCR assay (Thermo Fisher), and 100% concordance with the cobas BRAF assay
(Roche). There were 2 true discrepancies, most likely a result of sample quality or differences in sensi-
tivity between the assays that depend on set thresholds to determine the presence of mutations. Analysis
of the performance of the REB Array gave an overall sensitivity of 92%, with a positive predictive value
of 100% and negative predictive value of 84.24%.
Conclusion: The REB array is comparable to competing PCR methods with the additional advantages of
a broader range of mutations, simpliﬁed manual handling, and reduced overall cost per sample.
© 2016 Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The identiﬁcation of mutations within an expanding number of human cancers is important to guide choice of treatment, and pathol-
ogy departments are increasingly expected to provide rapid mutation detection.
Activating mutations in EGFR allow patients to be treated with EGFR inhibitors such as geﬁtinib (Iressa) or erlotinib (Tarceva). In the
same patients, identifying those with RAS mutations suggests that further testing would not be beneﬁcial as these are driver mutations
and mutually exclude other targetable mutations. In colorectal cancer, KRAS, NRAS and probably BRAF indicate a lack of response to anti-
EGFR antibody therapy [1]. BRAF is measured in all melanoma patients with metastatic disease to identify those that may beneﬁt from
vemurafenib and other BRAF inhibitors [2,3]. While other mutations in melanoma are of importance, around 40% of patients will have
BRAF mutations and do not require further testing for other mutations.
While larger centres are turning to next-generation sequencing (NGS) to assess mutations within cancers, most of the information ob-
tained is not currently actionable, and is not required routinely by clinical teams. As more targeted agents come onto the market, there
will be a need to identify mutations in a large number of genes, but this is not yet the case, and single gene PCR methods for the detec-
tion of common mutations still have an important role. Many PCR based assays for cancer markers exist; however, they typically suffer
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from either low sensitivity or are complicated to set up. Many only analyse a limited range of mutations in one gene, so that several tests
must be performed to cover several genes, adding signiﬁcant expense and time to the diagnostic pathway. We have therefore developed
a simple PCR-based array system to cover all of the common mutations in four actionable genes for colorectal cancer, lung cancer, and
melanoma, using a small amount of DNA that would be readily obtainable from biopsy as well as surgical material. The immediate need
for these patients is to identify mutations in EGFR, KRAS, NRAS, and BRAF. We have previously used 384 well TaqMan arrays® (Thermo
Fisher Scientiﬁc, Paisley, UK) to study gene expression in cancer [4–6] and they have been used for miRNA research for many years [7,8].
We realised that these had the potential to detect common mutations in several genes using a single array. This would not only stream-
line workﬂow in the laboratory but could also identify patient samples that may beneﬁt from next-generation sequencing and other molecular
methods to identify less common actionable mutations or gene ampliﬁcation.
The TaqMan Array (Thermo Fisher Scientiﬁc, Paisley, UK) was developed some 10 years ago by Applied Biosystems Inc., now part of
Thermo Fisher Scientiﬁc. It consists of a microﬂuidic card with 384 wells fed by eight ports. Each well is manufactured with primers and
probes lyophilised within it. The volume of each well is 1 μL, and the cards can be run on a variety of machines available from the man-
ufacturer. The REB Array (RAS-EGFR-BRAF) custom TaqMan Array card is intended for the detection of 44 somatic mutations in RAS (KRAS
and NRAS), EGFR and BRAF oncogenes (Table 1). TaqMan® Mutation Detection Assays (incorporated into the TaqMan Array card) were
designed based on competitive allele speciﬁc TaqMan® PCR (castPCR™) technology, which combines allele speciﬁc TaqMan® qPCR with
allele-speciﬁc MGB blocker oligonucleotides that effectively suppress nonspeciﬁc ampliﬁcation from the off-target allele. This gives en-
hanced speciﬁcity and sensitivity. The KRAS and BRAF assays we chose for the plate were the same as those used in our previous castPCR
plates [9], using a series of patient samples with known mutational status.
In this study, we compared the newly designed REB array to commercial (Therascreen and cobas) and in house PCR assays currently
in use to provide mutation analysis for patients with colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
2. Materials and Methods
2.1. Design of REB Arrays
Plates were designed as shown in Table 1. The COSMIC database was interrogated to identify mutations that were most commonly
reported. CastPCR assays for each of these were identiﬁed from the Life Technologies website (http://www.lifetechnologies
.com/it/en/home/life-science/pcr/real-time-pcr/real-time-pcr-assays/taqman-mutation-detection-assays/somatic-mutation-real-time
-pcr.html) and used to populate a spreadsheet, which was used to manufacture the array cards. TaqMan® Mutation Detection Assays for
the detection of mutant alleles must be run in parallel with corresponding wild type allele assays. This acts as a positive control for the
wild-type DNA. For each gene, a reference assay was therefore required. Each well on the 384 well REB Array contains a separate assay
(Fig. 1), allowing detection of a large number of targets without multiplexing. The card is divided along the rows into 8 separate chan-
nels, each containing 48 wells housing separate castPCR assays (four reference wild-type assays, 44 mutant assays) into which a single
sample is loaded with a single pipetting step. This elimination of individual well pipetting dramatically reduces the risk of contamina-
tion or operator error. As each port uses 48 wells, and the individual assays are very reliable, a single well is suﬃcient for each assay. It is,
however, good practice to run control plates at regular intervals, particularly with new plate or reagent batches. If duplicates or tripli-
cates for individual samples or controls are required, two or three ports respectively must be used.
Table 1
Complete list of castPCR assays incorporated within the TLDA card.
Column Row HGVS Row HGVS
1 A EGFR_rf B KRAS c.35G>C p.Gly12Ala
2 A EGFR c.2238_2252del15 p.L747_T751delLREAT B KRAS c.34G > C p.Gly12Arg
3 A EGFR c.2573T>G p.Leu858Arg; EGFR c.2572_2573CT>AG p.Leu858Arg B KRAS c.436G>A p.Ala146Thr
4 A EGFR c.2369C>T p.Thr790Met B KRAS c.37G>T p.Gly13Cys
5 A EGFR c.2582T>A p.Leu861Gln B KRAS c.183A>C p.Gln61H
6 A c.2303G > T p.Ser768Ile B KRAS c.182A>T p.Gln61Leu
7 A EGFR c.2156G>C Gly719Ala B KRAS c.37G>C p.Gly13Arg
8 A EGFR c.2155G>A p.Gly719Ser B NRAS_rf
9 A EGFR c.2155G>T P.Gly719Cys B NRAS c.37G>C p.Gly13Arg
10 A EGFR c.2125G>A p.Glu709Lys B NRAS c.34G>T p.Gly12Cys
11 A EGFR c.2126A>C p.Glu709Ala B NRAS c.34G>A p.Gly12Ser
12 A EGFR c.2311_2312insGCGTGGACA B NRAS c.38G > A p.Gly13Asp
13 A EGFR c.2319_2320ins9 B NRAS c.182A>T p.Gln61Leu; NRAS c.181_182CA>TT p.Gln61Leu
14 A BRAF_rf B NRAS c.35G>A p.Gly12Asp
15 A BRAF c.1799T>A p.Val600Glu B NRAS c.181C>A p.Gln61Lys
16 A BRAF c.1798_1799GT > AA p.Val600Glu B NRAS c.182A>G p.Gln61Arg; NRAS c.181_182CA>AG p.Gln61Arg
17 A BRAF c.1798_1799GT>AG p.Val600Arg B NRAS c.38G>T p.Gly13Val
18 A BRAF c.1799_1800TG>AT p.Val600Asp B NRAS c.35G>T p.Gly12Val
19 A KRAS_rf B NRAS c.183A>T p.Gln61His
20 A KRAS c.35G>A p.Gly12Asp B NRAS c.183A>C p.Gln61His
21 A KRAS c.35G>T p.Gly12Val B NRAS c.35G>C p.Gly12Ala
22 A KRAS c.38G > A p.Gly13Asp B NRAS c.37G>T p.Gly13Cys
23 A KRAS c.34G>T p.Gly12Cys B NRAS c.37G>A p.Gly13Ser
24 A KRAS c.34G>A p.Gly12Ser B NRAS c.38G>C p.Gly13Ala
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2.2. Patients and samples
We retrospectively identiﬁed a series of 96 patients with known mutational status and either extracted DNA from remaining formalin-
ﬁxed, paraﬃn-embedded FFPE blocks, or used stored DNA from the previous diagnostic PCR assays to validate the REB array, the characteristics
of which are summarised in Table 2 according to the BRISQ (Biospecimen reporting for improved study quality) guidance [10]. Our study
conforms to the tenets of the Declaration of Helsinki. Due to its retrospective nature for laboratory developed test validation, UK Health
Research Authority Ethics Committee approval was not required. Consent for publication is not required as long as the patients are not
identiﬁable.
FFPE blocks were identiﬁed for a series of patients with NSCLC (n = 42), colorectal cancer (n = 26), and melanoma (n = 28) for which
mutational analysis had previously been performed using Therascreen or castPCR. It should be noted that these were not consecutive or
randomly selected patients, but were instead chosen to reﬂect the range of mutations seen in our laboratory, for the purpose of clinical
validation of the REB array from samples with suﬃcient remaining tissue surplus to diagnostic requirements. Where it was necessary to
obtain further DNA, the same block was used when this could be identiﬁed from the pathology report.
2.3. DNA extraction
Areas of high cellularity cancer were identiﬁed by a histopathologist and marked on a slide. These were matched with the correspond-
ing block and case. Samples from the areas marked were punched out using a 1 mm diameter skin punch, as previously described [9].
The samples were then placed in the vial of a Maxwell DNA extraction robot (Promega, Southampton, UK) and DNA extracted according
to the manufacturer’s instructions. Stored or newly extracted DNA was checked for content and quality using a Nanodrop or Qubit in-
strument (both from Thermo Fisher Scientiﬁc) according to the manufacturer’s instructions.
2.4. REB arrays
Individual samples were diluted with MM and dH2O to give a concentration of 500 ng/mL in a volume of 100 μL (total DNA load 50 ng).
After mixing, 100 μL of each sample extract was added to each port of a REB array. The array plates were sealed, spun and placed in a
previously calibrated ViiA7 PCR machine (Thermo Fisher Scientiﬁc). Standard PCR conditions were used as follows: 50 °C for 2 min, fol-
lowed by 95 °C for 1 min, then 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. Each run took 118 minutes to complete.
For eﬃcient use of the REB arrays, samples must be grouped into batches of 7 (to ﬁll the 8 channel card, 7 samples + 1 negative control).
Smaller batch sizes require empty channels to be loaded with master mix before running, to avoid inaccurate data analysis by the ViiA7
software.
2.5. Therascreen EGFR RGQ PCR
The Therascreen assay (Qiagen Ltd, Manchester, UK) requires the preparation of eight different master mixes for the detection of the
full panel of mutations the assay covers, and was performed according to the manufacturer’s instructions. The Therascreen assay
Fig. 1. Diagram of the TaqMan Array ﬁll port and ﬁlling procedure (with permission from Thermo Fisher).
Table 2
BRISQ summary of sample characteristics [10].
Data Elements Examples
Biospecimen type Solid tissue
Anatomical site Variable – colorectal cancer, melanoma primary or lymph node, lung cancer primary or lymph node metastasis
Disease status of patients Patients with colorectal cancer, melanoma, or NSCLC
Clinical characteristics of patients No previous chemotherapy or targeted therapy
Vital state of patients Alive – biopsy material
Clinical diagnosis of patients Colorectal cancer, melanoma, or NSCLC
Pathology diagnosis Colorectal cancer, melanoma, or NSCLC
Collection mechanism Surgical, endoscopic or needle biopsy
Type of stabilisation 10% neutral buffered formalin
Type of long-term preservation Formalin ﬁxation and Paraﬃn embedding
Constitution of preservative 10% neutral-buffered formalin
Storage temperature 20 to 25 °C
Storage duration Up to 3 years
Shipping temperature Not applicable
Composition assessment and selection Minimum 10% neoplastic cells, material in block or extracted DNA surplus to diagnostic requirements
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requires the preparation of eight master mixes (seven mutation detection assays and one control assay), giving a total DNA requirement
of 80 ng. The assays were run in a Qiagen RotorGene QPCR instrument, and analysed according to manufacturer’s instructions.
2.6. Life Technologies KRAS castPCR
The castPCR assays were performed as recently reported [9], using standard operating procedures. Fifty nanograms of gDNA is re-
quired per reaction and up to 6 samples can be run per plate. The castPCR assay format is a predesigned 96-well plate in which the wells
are preloaded with the primers and probes for mutation and control assays (16 in total); therefore, the only reagents that need to be pre-
pared are PCR master mix and gDNA from each of the samples to be analysed. Every sample and control must be analysed by all 16 assays
(20 μL per reaction), and therefore the PCR master mix and gDNA are combined and diluted with nuclease free dH2O to achieve the correct
concentration and volume. The plates were run in a Life Technologies ViiA7 instrument (Thermo Fisher Scientiﬁc) according to manufa-
cturer’s instructions.
2.7. IonTorrent next generation sequencing
Sequencing was performed as previously described [11], with the following changes to accommodate IonChef loading of the IonTorrent
316 or 314 chips. Stored or newly extracted DNA was checked for content and quality using a Qubit 2.0 Fluorometer. Ten nanograms of
gDNA from each of the samples chosen for NGS analysis was combined with the Ampliseq™ reagents and primer pool for the Onconetwork
22 gene panel [11] and ampliﬁed for 22 cycles. After initial ampliﬁcation, the ampliﬁed products are partially digested before IonExpress
Adapters and Barcode sequences are ligated to the library fragments. Following barcoding, the libraries are cleaned up using a magnetic
bead method. The cleaned up products are then quantiﬁed by the Ampliseq Q-PCR method. Once the libraries have been successfully quan-
tiﬁed they are combined and diluted to 50 pM. For IonTorrent 314 chips, 3 libraries were combined per chip. These library pools were
then loaded into the IonChef instrument for further library preparation and chip loading. The loaded 314 chips were then run on the IonTorrent
PGM instrument according to manufacturer’s instructions. The Variant Caller plugin (included in the provided Ion Suite software) was
used to analyse the aligned sequence data for the identiﬁcation of hotspot mutations and novel variants.
2.8. Data analysis
The ViiA7 software produces a spreadsheet of Ct values for each well, clearly identiﬁed by sample number. The results from the spread-
sheets were then collected into a further summary spreadsheet in Excel (Microsoft). The following exclusions were applied:
• Samples with insuﬃcient DNA content (<50 ng total card input) were excluded from the analysis.
• Samples where one or more controls failed were excluded from the analysis as failed samples.
• Samples giving positive Ct values for targets on genes not present in the comparator assays were excluded from analysis as the sig-
niﬁcance of these results could not be determined.
Cases with discrepant results were sequenced on the IonTorrent PGM using the Onconetwork 22 gene panel [11]. Descriptive statis-
tics, including sensitivity and speciﬁcity, were produced using Excel.
3. Results
A total of 96 cases were included in the study, of which 26 had colorectal cancer, 42 had lung cancer, and 28 had melanoma. A summary
of the results for all three tumour types is shown in Table 3 and the accompanying STARD diagram (Fig. 2). Analysis of the performance
of the REB Array gave an overall sensitivity of 92%, with a positive predictive value of 100% and negative predictive value of 84.24%. Dis-
crepant cases were identiﬁed and subjected to further analysis as described below.
3.1. Lung cancer
A total of 42 samples were tested with 50 ng input DNA. Of these, 39/42 (92.9%) matched the results of previous Therascreen (Qiagen)
testing for EGFR. The three discordant samples were submitted to sequencing using the IonTorrent 22 gene panel with 10 ng input DNA
as previously described [11].
In one sample, the T790M mutation detected by Therascreen was not identiﬁed by REB array or IonTorrent NGS. The REB array did
detect a KRAS mutation (c.34G > C) with Ct < 36.5, conﬁrmed by IonTorrent NGS (COS518). This is regarded as a true discrepancy, incor-
rectly allocated by Therascreen, but correctly by REB array.
A second sample was reported as wild-type by the REB array, but had an Exon 20 mutation by Therascreen. IonTorrent sequencing
detected the Exon 20 mutation (c.2307_2308insGCCAGCGTG), matching the Therascreen result with 57% of 1520 reads. This is a rare in-
sertion, with just 10 entries on COSMIC, and was not included in the REB arrays assays, and does not represent a true discrepancy. The
Therascreen kit manual does not specify exactly which insertions Therascreen can detect, but says “3 insertions in exon 20 (detects the
presence of any of 3 insertions, but does not distinguish between them)”.
A third sample was reported as wild-type by the REB array, but had a S768I mutation (c.2303G > T) by Therascreen. The sample was
wild-type by Ion Torrent for EGFR. This is regarded as a true discrepancy, incorrectly allocated by Therascreen, but correctly by REB array.
After incorporating the ﬁndings of NGS analysis, the ﬁnal concordance of the REB Array for EGFR was 40/42 (95.2%). Sensitivity and
speciﬁcity for EGFR are therefore 92% and 100% respectively, with a negative and positive predictive value of 93% and 100% respectively.
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3.2. Colorectal cancer
For colorectal cancer, 26 samples were tested, but 7 samples were later found to have less than 50 ng input DNA or had failed controls
suggesting poor DNA quality. Initial analysis showed that 20/26 (77%) samples matched the results from previously used assays, but when
samples with insuﬃcient DNA content (<50 ng total card channel input) were excluded from the analysis, 18/19 (95%) were concordant.
The single discordant sample H09-322 was found to be KRAS mutant by castPCR (p.Gly13Asp, c38G > A) but was wild type by REB array.
IonTorrent sequencing detected a KRAS mutation at low level, c.38G > A (COSM532) with 12% of 1437 reads. The low number of reads
suggests that this may be a sensitivity issue.
Sensitivity and speciﬁcity for KRAS are therefore 92% and 100% respectively, with a negative and positive predictive value of 85.71%
and 100% respectively.
3.3. Melanoma
A total of 28 melanoma samples were tested, all of which had previously been sequenced for BRAF and NRAS mutations, and 10 of
which had previously been tested for BRAF mutations alone by cobas PCR (Roche). BRAF V600E mutation was identiﬁed in 12 cases, and
NRAS Q61K in 6 cases, NRAS Q61R in 1 case and NRAS G13R in 1 case. The remaining 8 cases were WT for NRAS and BRAF. Of the ten
cases tested by cobas, 4 had BRAF mutations at V600E: all were found by REB array and IonTorrent sequencing.
There was one possible discrepancy with sequencing in a case not previously tested by cobas: a rare BRAF V600E variant (BRAF
c.1798_1799GT > AA p.Val600Glu) was detected by REB array, which was found as an unexpected deletion by sequencing using a labora-
tory developed Ampliseq panel. This probably reﬂected a difference in PCR amplicons between Ampliseq and castPCR, and is not regarded
as a true discrepancy.
Table 3
Summary of mutations found by tumour type and gene. One lung cancer had two EGFR mutations, L861Q and G719X, so that a total of 19 mutations were reported from
42 cases, with 24 wild-type (WT) results. In colorectal cancer, of 19 samples with good quality DNA, 7 were WT with 10 KRAS and 2 NRAS mutations.
Gene HGVS Protein Lung Colorectal Melanoma
EGFR WT WT 24 7 8
EGFR c.2238_2252del15 p.L747_T751delLREAT Deletion 9
EGFR c.2573T>G p.Leu858Arg; EGFR c.2572_2573CT>AG p.Leu858Arg L858R 1
EGFR c.2369C>T p.Thr790Met T790M
EGFR c.2582T>A p.Leu861Gln L861Q 2
c.2303G > T p.Ser768Ile S768I 1
EGFR c.2156G>C Gly719Ala G719A
EGFR c.2155G>A p.Gly719Ser G719S 1
EGFR c.2155G>T P.Gly719Cys G719C
EGFR c.2125G>A p.Glu709Lys E709K
EGFR c.2126A>C p.Glu709Ala E709A
EGFR c.2311_2312insGCGTGGACA D770_N771insSVD
EGFR c.2319_2320ins9 H773_V774insNPH
BRAF BRAF c.1799T>A p.Val600Glu V600E 11
BRAF c.1798_1799GT > AA p.Val600Glu V600E 1
BRAF c.1798_1799GT>AG p.Val600Arg V600R
BRAF c.1799_1800TG>AT p.Val600Asp V600K
KRAS KRAS c.35G>A p.Gly12Asp G12D 1 4
KRAS c.35G>T p.Gly12Val G12V 1
KRAS c.38G > A p.Gly13Asp G13D 2
KRAS c.34G>T p.Gly12Cys G12C 2 1
KRAS c.34G>A p.Gly12Ser G12S
KRAS c.35G>C p.Gly12Ala G12A 2
KRAS c.34G > C p.Gly12Arg G12R 1
KRAS c.436G>A p.Ala146Thr A146T
KRAS c.37G>T p.Gly13Cys G13C
KRAS c.183A>C p.Gln61H Q61H
KRAS c.182A>T p.Gln61Leu Q61L
KRAS c.37G>C p.Gly13Arg G13R 1
NRAS NRAS c.37G>C p.Gly13Arg G13R 1
NRAS c.34G>T p.Gly12Cys G12C
NRAS c.34G>A p.Gly12Ser G12S
NRAS c.38G > A p.Gly13Asp G13D
NRAS c.182A>T p.Gln61Leu; NRAS c.181_182CA>TT p.Gln61Leu Q61L
NRAS c.35G>A p.Gly12Asp G12D 1
NRAS c.181C>A p.Gln61Lys Q61K 1 1
NRAS c.182A>G p.Gln61Arg; NRAS c.181_182CA>AG p.Gln61Arg Q61R 6
NRAS c.38G>T p.Gly13Val G13V
NRAS c.35G>T p.Gly12Val G12V
NRAS c.183A>T p.Gln61His Q61H
NRAS c.183A>C p.Gln61His Q61H
NRAS c.35G>C p.Gly12Ala G12A
NRAS c.37G>T p.Gly13Cys G13C
NRAS c.37G>A p.Gly13Ser G13S
NRAS c.38G>C p.Gly13Ala G13A
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Final concordance was therefore 28/28 (100%). Sensitivity and speciﬁcity for BRAF were both 100%, with negative and positive pre-
dictive values of 100%.
4. Discussion
There was generally good concordance between REB array and previous mutational analysis by either PCR or sequencing, though four
true discrepant results were identiﬁed: two in EGFR, one in BRAF, and one in KRAS. Following sequencing, only one of these cases (the
KRAS mutation in a colorectal cancer) was found to be a REB array miss, and this showed low reads suggesting low allelic frequency. It
should be noted that for many of the cases (45%) stored DNA was used. The quantity of DNA remaining may therefore have been subop-
timal and in several cases re-extraction of DNA was successful in ﬁnding the mutation previously identiﬁed. This may explain the KRAS
case missed by REB array. Some loss of sensitivity is expected by performing castPCR within TaqMan arrays due to dilution in the plate.
Two EGFR mutations called WT by Therascreen were picked up by the REB array. The EGFR mutant case missed by REB array had a
rare Exon 20 mutation, which is not present on the REB array, though it is found by Therascreen. This is therefore not regarded as a true
discrepancy.
The melanoma cases show excellent concordance between all three assays (REB array, cobas, and Ampliseq panel). It should be noted
that no V600K cases were included in the series of samples used for validation: this mutation was initially omitted from this version of
the REB array, but has now been included as our sequencing and other published data [12,13] suggest that such cases may account for up
to 10% of BRAF mutated melanomas, which we would otherwise miss unless sequencing was undertaken.
Discrepancies between mutation assays are to be expected, since calling mutations by PCR is based on PCR eﬃciency and thresholds,
which differ between technologies, and primer pairs used for PCR differ between assays, including targeted sequencing panels. Equally,
particularly for EGFR in this instance, amplicon size varies with the technology used, and may be a further source of difference. The KRAS
technology was castPCR in both the REB array and the standard assay, and the performance of these assays in TaqMan array plates versus
96 well plates was comparable, apart from a single discrepancy, which probably reﬂects slightly lower sensitivity in the TaqMan array.
Use of a third technology is often necessary to determine the true status of the sample for accuracy estimation. In this instance, the IonTorrent
Colon and Lung Cancer panel proved very helpful in deciding the true status of discrepant samples, as it has the ability to use very small
amounts of DNA (10 ng) in comparison with castPCR (50 ng) and Therascreen (80 ng).
In our view, the advantages of REB array outweigh its any minor loss of sensitivity, since it allows coverage of a greater number of
genes and mutations than its comparators in this study for either lung or colorectal cancer. There is certainly a need for multiple gene
Potentially eligible participants
n = 96
Eligible participants
n = 89
Index test
n = 89
Index test negative
n = 39 (WT)
Index test positive
n = 50 (Mut)
Index test inconclusive
n = 0
Reference standard 
n = 39
Reference standard 
n = 50
Reference standard 
n = 0
Final diagnosis
Mutation present (n = 1)
Mutation absent (n = 37)
Inconclusive (n = 1)
Final diagnosis
Mutation present (n = 49)
Mutation absent (n = 1)
Inconclusive (n = 0)
Final diagnosis
Mutation present (n = 0)
Mutation absent (n = 0)
Inconclusive (n = 0)
Excluded
n = 7
Insufficient DNA (n = 7)
No Index Test
n = 0
No reference standard
n = 0
No reference standard
n = 0
No reference standard
n = 0
r
Fig. 2. STARD diagram. The REB array is the Index test, and the reference test is taken as EGFR for lung cancer, KRAS for colorectal cancer, and BRAF for melanoma. One
NSCLC case found WT by REB array was regarded as mutation inconclusive, as this test was not present on the array but was detected by Therascreen.
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assessment without the expense of NGS, and this is one solution. No PCR assay is capable of ﬁnding complete coverage of all the muta-
tions that may be present, but this approach does allow commonmutations to be detected accurately, and in patients with these mutations,
the effect of treatment is known.
The other advantage of the REB Array is its ease of use. Loading of DNA is simple and rapid, and less prone to pipetting errors than
Therascreen or castPCR. The assay takes 2 hours to perform, and even allowing a further 90 min for DNA extraction; results can be re-
ported in a morning, compared with three days for IonTorrent NGS using current protocols. There is no question that this is an advantage
to clinical laboratories, which are often under considerable pressure to produce rapid results for oncologists, particularly in lung cancer.
We have used the CMD-ImPACT tool (http://www.rcpath.org/cmd-impact) to cost the tests involved in this pathway. In our laboratory,
use of the REB array to triage patients for ALK immunohistochemistry and IonTorrent NGS is the most cost-effective option, partly because
savings in staff time outweigh the cost of the plates.
Our intended use of the REB array is as a simple, rapid triage test allowing eﬃcient use of expensive NGS facilities, while meeting guid-
ance for molecular pathology testing [14]. This is particularly important in lung cancer, where biopsies are often small and diﬃcult to
repeat. Other laboratories may wish to adopt different approaches, in consultation with their clinical team, but reﬂex testing of samples
can be very cost-effective [14], and in our practice, the use of the REB array will make it affordable to use NGS for mutation detection
[11,15] in patients without common actionable mutations. There is a wide range of competing technologies for PCR-based detection of
cancer mutations. Therascreen and cobas are both commonly used, and the new cassette-based Idylla™ system (Biocartis), which auto-
mates extraction and measurement, is also gaining market share as it avoids the need for molecular laboratory expertise [16–18]. Finally,
antibodies to common mutations are now available and could be used as screening methods [19,20]. The choice of method is an individ-
ual decision for those providing cancer pathology services, but can be informed by comparative studies [9,14,21–24]. Most newer methods
have subjected to such assessments [16–18].
In conclusion, we have developed a rapid assay system for common actionable mutations in colorectal cancer, lung cancer and mela-
noma. This newly validated assay has the potential to personalise patient treatment and direct further investigation in those without actionable
mutations.
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